| Dr Asim Elahi, MD | |
|
75 N Country Rd, Port Jefferson, NY 11777-2119 | |
| (631) 473-1320 | |
| Not Available |
| Full Name | Dr Asim Elahi |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 20 Years |
| Location | 75 N Country Rd, Port Jefferson, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063837912 | NPI | - | NPPES |
| 7100348310 | Medicaid | KY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 286280-1 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Centerlight Certified Home Health Agency | Brooklyn, NY | Home health agency |
| Wyckoff Heights Medical Center | Brooklyn, NY | Hospital |
| Harlem Hospital Center | New york, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Harlem Medical Associates, Pc | 9335321223 | 219 |
| Wyckoff Professional Medical Services Pc | 6406748607 | 145 |
News Archive
Modern Healthcare: "The Senate is expected to vote on a fiscal 2010 Defense appropriations bill by this weekend that would extend a health insurance subsidy for laid-off workers through February 2010. The House has approved the subsidy extension for the COBRA program, which was tucked into the $636.3 billion Defense appropriations bill."
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that the European Commission has granted orphan medicinal product designation for RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21") for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy.
OSI Pharmaceuticals, Inc. and Genentech, Inc., a wholly owned member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for Tarceva® (erlotinib) as a first-line maintenance therapy in advanced non-small cell lung cancer (NSCLC) by an additional 90 days.
Atrium Innovations Inc. (TSX: ATB), a leading developer, manufacturer and marketer of science-based and professionally supported products for the Health and Nutrition industry, today announced various initiatives to support the development of its Wobenzym(R) brand in Germany.
Shamir Optical Industry Ltd. Kibbutz Shamir and Essilor International today announced that they have signed an agreement whereby Essilor will, through a series of transactions, acquire 50% of Shamir Optical. As a result of these transactions, Kibbutz Shamir and Essilor will each own 50% of Shamir Optical.
› Verified 5 days ago
| Entity Name | Wyckoff Professional Medical Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659710796 PECOS PAC ID: 6406748607 Enrollment ID: O20040324001805 |
News Archive
Modern Healthcare: "The Senate is expected to vote on a fiscal 2010 Defense appropriations bill by this weekend that would extend a health insurance subsidy for laid-off workers through February 2010. The House has approved the subsidy extension for the COBRA program, which was tucked into the $636.3 billion Defense appropriations bill."
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that the European Commission has granted orphan medicinal product designation for RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21") for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy.
OSI Pharmaceuticals, Inc. and Genentech, Inc., a wholly owned member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for Tarceva® (erlotinib) as a first-line maintenance therapy in advanced non-small cell lung cancer (NSCLC) by an additional 90 days.
Atrium Innovations Inc. (TSX: ATB), a leading developer, manufacturer and marketer of science-based and professionally supported products for the Health and Nutrition industry, today announced various initiatives to support the development of its Wobenzym(R) brand in Germany.
Shamir Optical Industry Ltd. Kibbutz Shamir and Essilor International today announced that they have signed an agreement whereby Essilor will, through a series of transactions, acquire 50% of Shamir Optical. As a result of these transactions, Kibbutz Shamir and Essilor will each own 50% of Shamir Optical.
› Verified 5 days ago
| Entity Name | Hospitalist Medicine Physicians Of New York Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205944329 PECOS PAC ID: 5597767129 Enrollment ID: O20070209000383 |
News Archive
Modern Healthcare: "The Senate is expected to vote on a fiscal 2010 Defense appropriations bill by this weekend that would extend a health insurance subsidy for laid-off workers through February 2010. The House has approved the subsidy extension for the COBRA program, which was tucked into the $636.3 billion Defense appropriations bill."
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that the European Commission has granted orphan medicinal product designation for RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21") for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy.
OSI Pharmaceuticals, Inc. and Genentech, Inc., a wholly owned member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for Tarceva® (erlotinib) as a first-line maintenance therapy in advanced non-small cell lung cancer (NSCLC) by an additional 90 days.
Atrium Innovations Inc. (TSX: ATB), a leading developer, manufacturer and marketer of science-based and professionally supported products for the Health and Nutrition industry, today announced various initiatives to support the development of its Wobenzym(R) brand in Germany.
Shamir Optical Industry Ltd. Kibbutz Shamir and Essilor International today announced that they have signed an agreement whereby Essilor will, through a series of transactions, acquire 50% of Shamir Optical. As a result of these transactions, Kibbutz Shamir and Essilor will each own 50% of Shamir Optical.
› Verified 5 days ago
| Entity Name | Harlem Medical Associates, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487957692 PECOS PAC ID: 9335321223 Enrollment ID: O20110315000005 |
News Archive
Modern Healthcare: "The Senate is expected to vote on a fiscal 2010 Defense appropriations bill by this weekend that would extend a health insurance subsidy for laid-off workers through February 2010. The House has approved the subsidy extension for the COBRA program, which was tucked into the $636.3 billion Defense appropriations bill."
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that the European Commission has granted orphan medicinal product designation for RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21") for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy.
OSI Pharmaceuticals, Inc. and Genentech, Inc., a wholly owned member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for Tarceva® (erlotinib) as a first-line maintenance therapy in advanced non-small cell lung cancer (NSCLC) by an additional 90 days.
Atrium Innovations Inc. (TSX: ATB), a leading developer, manufacturer and marketer of science-based and professionally supported products for the Health and Nutrition industry, today announced various initiatives to support the development of its Wobenzym(R) brand in Germany.
Shamir Optical Industry Ltd. Kibbutz Shamir and Essilor International today announced that they have signed an agreement whereby Essilor will, through a series of transactions, acquire 50% of Shamir Optical. As a result of these transactions, Kibbutz Shamir and Essilor will each own 50% of Shamir Optical.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Asim Elahi, MD 32 Woodstork Drive, Mount Sinai, NY 11766 Ph: (367) 257-2122 | Dr Asim Elahi, MD 75 N Country Rd, Port Jefferson, NY 11777-2119 Ph: (631) 473-1320 |
News Archive
Modern Healthcare: "The Senate is expected to vote on a fiscal 2010 Defense appropriations bill by this weekend that would extend a health insurance subsidy for laid-off workers through February 2010. The House has approved the subsidy extension for the COBRA program, which was tucked into the $636.3 billion Defense appropriations bill."
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that the European Commission has granted orphan medicinal product designation for RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21") for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy.
OSI Pharmaceuticals, Inc. and Genentech, Inc., a wholly owned member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for Tarceva® (erlotinib) as a first-line maintenance therapy in advanced non-small cell lung cancer (NSCLC) by an additional 90 days.
Atrium Innovations Inc. (TSX: ATB), a leading developer, manufacturer and marketer of science-based and professionally supported products for the Health and Nutrition industry, today announced various initiatives to support the development of its Wobenzym(R) brand in Germany.
Shamir Optical Industry Ltd. Kibbutz Shamir and Essilor International today announced that they have signed an agreement whereby Essilor will, through a series of transactions, acquire 50% of Shamir Optical. As a result of these transactions, Kibbutz Shamir and Essilor will each own 50% of Shamir Optical.
› Verified 5 days ago
Jay M Barbakoff, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 60 North Country Rd, Suite 203, Port Jefferson, NY 11777 Phone: 631-928-3444 Fax: 877-434-7939 | |
Dr. William L. Taibi, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 710 Main St, Port Jefferson, NY 11777 Phone: 631-474-4000 Fax: 631-474-4011 | |
Arain Mohammad Nawaz, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 620 Belle Terre Rd, Suite 1, Port Jefferson, NY 11777 Phone: 631-928-0240 Fax: 631-928-0855 | |
Joan C Faro, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 75 N Country Rd, Port Jefferson, NY 11777 Phone: 631-476-2866 Fax: 631-476-2874 | |
Dr. Mark J. Kropf, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 200 Belle Terre Road, Suite 100, Port Jefferson, NY 11777 Phone: 631-331-6090 Fax: 631-474-7855 | |
Javeria Nasim, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 75 N Country Rd, Port Jefferson, NY 11777 Phone: 631-473-1320 Fax: 631-686-7972 |